Chronic Myeloid Leukemia Outlook: The Future of CML Therapy
|
|
- Julie Lewis
- 6 years ago
- Views:
Transcription
1 Chronic Myeloid Leukemia Outlook: The Future of CML Therapy Neil Shah, MD PhD Edward S. AgenoDistinguished Professor in Hematology/Oncology UCSF School of Medicine San Francisco, California
2 Progression of CML Bcr-Abl HSC CML-BP (myeloid) CMP CLP CML-BP (lymphoid) Additional mutations GMP MEP Additional mutations MEG CML-CP Blast Phase >30% blasts ~2/3 of patients have myeloid blast crisis ~1/3 have lymphoid blast crisis Very poor prognosis G M RBC Platelets T cell Chronic Phase Myeloid hyperplasia 10% 15% blasts Natural history of disease progression, 3-5 years B cell Accelerated Phase >15%, <30% blasts Basophilia New cytogenetic abnormalities in 50% to 80% of patients
3 Chronic phase CML is characterized by myeloid expansion HSC LT HSC LT HSC ST HSC ST MPP MPP CLP CMP CLP CMP MEP GMP GMP GrP Gr Normal hematopoiesis CML
4 15-20 percent of chronic phase CML patients do not achieve deep responses HSC LT HSC LT HSC ST HSC ST MPP MPP CLP CMP CLP CMP GMP GMP GrP GrP Gr Gr CML (untreated) CML in morphologic remission, but without cytogenetic remission
5 Treatment of CML with TKIs commonly results in profound disease burden reduction, but it is believed that diseased stem cells persist in most if not all patients HSC LT HSC LT HSC ST HSC ST MPP MPP CLP CMP CLP CMP GMP MEP GMP GrP Gr CML (untreated) CML in complete cytogenetic remission
6 Disease Cure Definitions No evidence of disease by any testing method Given limitations of all testing methods (limited sampling), it is not possible to convincingly demonstrate a complete absence of disease Ability to stop treatment and never suffer disease recurrence Depends upon the expected natural lifespan of patients who have CML (can be >50 years in younger patients) It may be decades before we can convincingly state that a CML patient is cured
7 ENESTnd 5-Year Update Incidence of MR 4.5 : linearly increasing Patients With MR 4.5, % Nilotinib 300 mg BID (n = 282) Nilotinib 400 mg BID (n = 281) Imatinib 400 mg QD (n = 283) 6% to 10% By1 Year a 11%, P< %, P< % By4 Years a 40%, P< %, P= % to 17% 23% By5 Years a 54%, P< %, P< % to 23% % Time Since Randomization, Calendar Years MR 4.5, molecular response 4.5-logs (BCR-ABL IS %). a Cumulative response rates reported consider each year to consist of twelve 28-day cycles. 7 Data cutoff: May 22, 2013
8 Incidence of MR 4.5 : linearly increasing DASISION 4-Year Follow-up Dasatinib 100 mg QD Imatinib 400 mg QD 60 P=0.030 MR % With MR % 18% 23% 34% 21% 37% 30% 10 9% 12% 0 2% MR 4.5 = BCR-ABL (IS) % IS = International Scale Months 8
9 PROVOCATIVE ANECDOTAL CASES
10 Case 1 (continued) October 2001 Initiated imatinib400 mg daily and rapidly achieved a complete hematologic response.
11 Case 1 (continued) October 2001 Initiated imatinib400 mg daily and rapidly achieved a complete hematologic response. June 2002 Bone marrow biopsy morphologic remission, mildly hypocellular. Cytogenetics: 46,XX[20] (complete cytogenetic response).
12 Case 1 (continued) October 2001 Initiated imatinib400 mg daily and rapidly achieved a complete hematologic response. June 2002 Bone marrow biopsy morphologic remission, mildly hypocellular. Cytogenetics: 46,XX[20] (complete cytogenetic response). July 2003 Imatinib held due to pregnancy.
13 Case 1 (continued) October 2001 Initiated imatinib400 mg daily and rapidly achieved a complete hematologic response. June 2002 Bone marrow biopsy morphologic remission, mildly hypocellular. Cytogenetics: 46,XX[20] (complete cytogenetic response). July 2003 Imatinib held due to pregnancy. Early 2004 Delivered a healthy child. Despite lengthy interruption of imatinib, CBC was normal. BCR-ABL transcript was undetectable by quantitative PCR.
14 Case 1 (continued) October 2001 Initiated imatinib400 mg daily and rapidly achieved a complete hematologic response. June 2002 Bone marrow biopsy morphologic remission, mildly hypocellular. Cytogenetics: 46,XX[20] (complete cytogenetic response). July 2003 Imatinib held due to pregnancy. Early 2004 Delivered a healthy child. Despite lengthy interruption of imatinib, CBC was normal. BCR-ABL transcript was undetectable by quantitative PCR. Remained off TKI therapy.
15 Case 1 (continued) October 2001 Initiated imatinib400 mg daily and rapidly achieved a complete hematologic response. June 2002 Bone marrow biopsy morphologic remission, mildly hypocellular. Cytogenetics: 46,XX[20] (complete cytogenetic response). July 2003 Imatinib held due to pregnancy. Early 2004 Delivered a healthy child. Despite lengthy interruption of imatinib, CBC was normal. BCR-ABL transcript was undetectable by quantitative PCR. Remained off TKI therapy. Late 2009 Delivered a second healthy child. Remained off TKI therapy.
16 Case 1 (continued) October 2001 Initiated imatinib400 mg daily and rapidly achieved a complete hematologic response. June 2002 Bone marrow biopsy morphologic remission, mildly hypocellular. Cytogenetics: 46,XX[20] (complete cytogenetic response). July 2003 Imatinib held due to pregnancy. Early 2004 Delivered a healthy child. Despite lengthy interruption of imatinib, CBC was normal. BCR-ABL transcript was undetectable by quantitative PCR. Remained off TKI therapy. Late 2009 Delivered a second healthy child. Remained off TKI therapy. June 2013 CBC remains normal and BCR-ABL quantitative PCR remains undetectable.
17 Case 2 November 1998 Diagnosed with chronic phase CML. Simultaneously diagnosed with kidney cancer and underwent nephrectomy Summer 1999 Initiated interferon but did not have a complete hematologic response. Discontinued interferon after ~6 months January 2000 Initiated imatinib(phase II study) April 2000 Cytogenetics reveal Ph chromosome in 6 of 20 metaphases July 2000 Achieved complete cytogenetic response. Over the next seven years, PCR revealed a low but detectable BCR-ABL transcript October 2007 Found to have metastatic kidney cancer. Prescribed preoperative bevacizumabbut had difficulty tolerating it in combination with imatinib. Imatinib held temporarily. BCR-ABL transcript level was
18 Follow-up PCRs: Case 2 (continued) 1/ Remained off imatinib
19 Case 2 (continued) Follow-up PCRs: 1/ Remained off imatinib 4/08 weakly positive 7/08 weakly positive 10/08 weakly positive 3/09 weakly positive 6/09 weakly positive 10/09 weakly positive 1/10 weakly positive
20 Case 2 (continued) Follow-up PCRs: 1/ Remained off imatinib 4/08 weakly positive 7/08 weakly positive 10/08 weakly positive 3/09 weakly positive 6/09 weakly positive 10/09 weakly positive 1/10 weakly positive 5/10 negative 8/10 weakly positive 12/10 negative 3/11 weakly positive 6/11 negative 9/11 negative 1/12 negative 4/12 negative 7/12 negative 10/12 negative 1/13 negative 8/13 negative
21 Patients who maintain CMR of imatinib commonly have evidence of BCR-ABL when assessed with a more sensitive genomic DNA based test Ten patients with loss of CMR had rising gdna PCR levels, whereas gdna was detectable in 7/8 patients with sustained CMR (follow-up months) and PCR levels were stable
22 CML patients treated with dasatinib frequently have clonal T/NK-cell expansion which may be associated with improved response rates and a distinct toxicity profile Ten patients with loss of CMR had rising gdnapcr levels, whereas gdna was detectable in 7/8 patients with sustained CMR (follow-up months) and PCR levels were stable
23 Ph+ ALL patients treated with dasatinib who develop lymphocytosis may have better long-term outcomes
24 Case 2 (continued) Follow-up PCRs: 1/ Remained off imatinib 4/08 weakly positive 7/08 weakly positive 10/08 weakly positive 3/09 weakly positive 6/09 weakly positive 10/09 weakly positive 1/10 weakly positive 5/10 negative 8/10 weakly positive 12/10 negative 3/11 weakly positive 6/11 negative 9/11 negative 1/12 negative 4/12 negative 7/12 negative 10/12 negative 1/13 negative 8/13 negative Lymphocytosis first developed in December In August 2010, flow cytometric studies revealed a T/NK population; no evidence of CLL
25 Case 2 (continued) How can this patient s molecular response be explained? Possible explanations include: PCR is detecting a long-lived terminally-differentiated BCR-ABL+ population (e.g. memory B-or T-cells), and not CML stem cells. Stem cells in this case may have been eradicated. CML stem cells are held in check by the immune system. Is the T/NK proliferation evidence of immune activation? Could imatinib negatively impact immune surveillance? Could his brief treatment with interferon in 1999 be responsible? Since a 4.5 log reduction is an arbitrary threshold, is it possible that a substantial proportion of patients with lesser degrees of molecular remission (e.g. stable 3-log reduction) can stop TKI therapy and have prolonged treatment-free remissions?
26 CML STEM CELLS Can they be eradicated?
27 A Hedgehog pathway inhibitor (Smo) in conjunction with a BCR-ABL inhibitor suppresses CML stem cells in vitro (LTC-IC assays) Dierks C et al, Cancer Cell 14:
28 Mechanisms of Leukemic Stem Cell Resistance Stem Cell Niche Quiescence Self Renewal HSC Progenitors T Cells B Cells NK Cells Granulocytes Monocytes TGFbeta Inhibitor Arsenic trioxide FOXO PML Wnt Hedgehog SMO Inhibitor Erythrocytes Platelets Plerixafor JAK Inhibitor Chemokines Cytokines Zileuton Alox5 FTY720 PP2A Acetylation Rac GTPases LSC Autophagy inhibitors HDAC Inhibitors Bcr-Abl TKI T Cells B Cells NK Cells Granulocytes Monocytes Erythrocytes Platelets Chronic Phase CML
29 CML Stem Cell Eradication Strategies A number of self-renewal pathways have been implicated as critically important in CML stem cells in vitro, and strategies to exploit this information clinically are ongoing TKIs + interferon Smo inhibitors (dasatinib or bosutinib with PF , dasatinib plus BMS ) Autophagy inhibitors (hydroxychloroquine) Imatinib with or without hydroxychloroquine in newly diagnosed CML patients HDAC inhibitors (imatinib with panobinostat) PML inhibitors (AsO3) with BCR-ABL TKIs 5-LO inhibitors (Zileuton with imatinib) BCR-ABL protein stability inhibitors (HSP90 inhibitors) JAK inhibitors (ruxolitinib) TGF-beta/FOXO inhibitors Activation of p53 by inhibiting SIRT1 TNF-alpha inhibitors Preventing quiescence by targeting FBXW7
30 CML Stem Cell Eradication Strategies: Challenges Given the possibility that CML stem cells may be very similar to normal stem cells, could all of these pathways truly be critical for the survival of stem cells of CML patients? How to prioritize amongst these many options? Clinical proof-of-concept will require many years of follow-up (complete molecular remission may be an early indicator). In light of the current expected outlook of CML patients with TKI therapy, therapeutic strategies to eradicate CML stem cells must be safe and ideally well-tolerated -in the absence of known activity, even moderate toxicities are difficult to justify
31 CML Stem Cells: Concluding Thoughts Molecular responses in TKI-treated patients deepen over time, suggesting a gradual elimination of long-lived CML cells that may or may not represent CML stem cells. The ability of some patients to discontinue treatment without evidence of relapse for ten years suggests that some patients may be cured with TKI therapy. While a number of potential interventions to hasten CML stem cell elimination have been identified, the pathway to proof-ofconcept is complicated, and it will likely be years if not decades before definitive proof can be obtained Immunotherapeutic approaches (chimeric antigen receptor T- cells) are demonstrating substantial activity in lymphoid malignancies. Whether myeloid leukemiascan be safely targeted is not clear.
CML Clinical Case Scenario
CML Clinical Case Scenario Neil Shah, MD, PhD Edward S. Ageno Distinguished Professor in Hematology/Oncology Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive Cancer Center at
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationGetting to the root of Cancer
Cancer Stem Cells: Getting to the root of Cancer Dominique Bonnet, Ph.D Senior Group Leader, Haematopoietic Stem Cell Laboratory Cancer Research UK, London Research Institute Venice, Sept 2009 Overview
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationFuture of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
Future of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Primitive sleeping BCR-ABL-positive leukemic stem cells are less
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationChronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE
Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE If searched for the ebook by DEISSEROTH Chronic Myelogenous Leukemia (Hematology) in pdf format, in that case you come on to correct
More informationChronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018
Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018 Disclosures Richard A. Larson, MD Research funding to the University of Chicago: Astellas Celgene Daiichi
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More informationDati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
More informationRecent advances in the path toward the cure for chronic myeloid leukemia
VOLUME 46 ㆍ NUMBER 3 ㆍ September 2011 THE KOREAN JOURNAL OF HEMATOLOGY REVIEW ARTICLE Recent advances in the path toward the cure for chronic myeloid leukemia Dong-Wook Kim Department of Hematology, Seoul
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationThe Hierarchical Organization of Normal and Malignant Hematopoiesis
The Hierarchical Organization of Normal and Malignant Hematopoiesis NORMAL Hematopoie2c Stem Cell (HSC) Leukemia Stem Cells (LSC) MPP MLP CMP Leukemic Progenitors MEP GMP B/NK ETP Leukemic Blasts Erythrocytes
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationImatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationMP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationMolecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. Masahiro Kizaki Editor
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia Masahiro Kizaki Editor 123 Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia ThiS is a FM Blank Page Masahiro Kizaki
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationAccepted Manuscript. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. Pradnya Chopade, Luke P.
Accepted Manuscript Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors Pradnya Chopade, Luke P. Akard PII: S2152-2650(18)30343-4 DOI: 10.1016/j.clml.2018.06.029
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationMYELOPROLIFERATIVE NEOPLASMS. Matthew Ulrickson, MD Banner MD Anderson Cancer Center September 20, 2016
MYELOPROLIFERATIVE NEOPLASMS Matthew Ulrickson, MD Banner MD Anderson Cancer Center September 20, 2016 Matthew.Ulrickson@bannerhealth.com Objectives Discuss an approach to increased cell counts Discuss
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationCML: Role of combination treatments, Interferon and immunotherapy in CML
CML: 2017 Role of combination treatments, Interferon and immunotherapy in CML Andreas Burchert Philipps Universität Marburg Universitätsklinikum Gießen und Marburg GmbH Key Developments that will Change
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More information9/26/2018. Learning Objectives
ADVANCES IN CHRONIC MYELOID LEUKEMIA Alison Wakoff Loren, MD, MSCE Associate Professor of Medicine Director, Blood & Marrow Transplantation Vice Chair, Faculty Development Department of Medicine Perelman
More informationExecutive summary Overview
Executive summary Overview In this appraisal, we have demonstrated that dasatinib is clinically more effective, as well as more cost effective, than imatinib, the current standard of care. In the pivotal
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More informationOverview of mathematical biological models and their application in CML research
Overview of mathematical biological models and their application in CML research March 27 th 2015 Christina Fitzmaurice, MD, MPH Faculty discussants: Vivian Oehler, MD FHCRC/UW William Hazelton, PhD FHCRC
More informationAGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA.
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA Michele.Baccarani@unibo.it EUROPEAN LEUKEMIANET 2013 (Blood 2013;122:885 892). RESPONSE
More informationForm 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationIl controllo della malattia minima residua Daniela Cilloni Università di Torino
Milano, 18-21 ottobre 2009 Il controllo della malattia minima residua Daniela Cilloni Università di Torino Response to imatinib Two main aspects to be considered: Degree of response Time to achieve it
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationHematopathology Case Study
www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationNovel approaches to therapy in CML
CHRONIC MYELOID LEUKEMIA: WHERE ARE WE IN THE CURRENT TKI ERA? Novel approaches to therapy in CML Ravi Bhatia Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham,
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationPhiladelphia Positive (Ph+) Chronic Myeloid Leukaemia
Advocacy toolkit In this toolkit, we take a look into the treatments for Philadelphia-positive Chronic Myeloid Leukaemia (CML) that have led to treatment free remission (TFR) being one of the biggest topics
More informationTime slots Sessions Location December 5 th (Friday) Friday Scientific Workshop on Myeloid Development
Overview of CML related sessions at the 56 th ASH Annual Meeting in San Francisco (USA) December 5-9, 2014 Time slots Sessions Location December 5 th (Friday) 13.00-19.15 Friday Scientific Workshop on
More informationStudying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
A service of the U.S. National Institutes of Health Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY) This study is currently recruiting participants.
More informationBOSULIF (bosutinib) oral tablet
BOSULIF (bosutinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationCML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationHematopoiesis. BHS Liège 27/1/2012. Dr Sonet Anne UCL Mont-Godinne
Hematopoiesis BHS Liège 27/1/2012 Dr Sonet Anne UCL Mont-Godinne Hematopoiesis: definition = all the phenomenons to produce blood cells Leukocytes = White Blood Cells Polynuclear = Granulocytes Platelet
More informationA COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA.
A COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA Melea Ward A dissertation submitted to the faculty of the University of
More informationDevelopment of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) CIRM/CSCC disease team grant CIRM PI: D. Carson co-pi: C. Jamieson CSCC PI: J. Dick co-pi: J. Wang Project leaders: ROR1 mab Development:
More informationLeukemias and Lymphomas Come From Normal Blood Cells
Leukemias and Lymphomas Come From Normal Blood Cells by Steve Anderson, Ph.D. Steve Anderson has a Ph.D. in Immunology with 25 years experience in biomedical research. His scientific expertise includes
More informationHull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Chronic Myeloid Leukaemia
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Chronic Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationSupplementary Online Content
Supplementary Online Content Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M. Use of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and metaanalysis
More informationNormal & Leukaemic haematopoiesis. Dr. Liu Te Chih Dept of Haematology / Oncology National University Health Services Singapore
Normal & Leukaemic haematopoiesis 2010 Dr. Liu Te Chih Dept of Haematology / Oncology National University Health Services Singapore Use of Immunophenotyping today Lineage assignment Differentiation of
More informationNovel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells
Review Article Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells Kazuhito Naka, 1 Takayuki Hoshii 1 and Atsushi Hirao 1,2,3 1 Division of Molecular
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationGleevec. Gleevec (imatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.74 Subject: Gleevec Page: 1 of 6 Last Review Date: June 24, 2016 Gleevec Description Gleevec (imatinib)
More information